Ocugen Advances OCU410 into Phase 3 Gene Therapy Trial
MALVERN, Pa., Sept. 1, 2026 Ocugen, Inc. has announced that the first patient has been dosed in the global...
dry age-related macular degeneration
Advertisement
Ocugen Receives FDA RMAT Designation for OCU410 in Geographic Atrophy
MALVERN, Pa., July 29, 2026 Ocugen, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative...
Annexon Advances Vonaprument with Phase 2 Data
BRISBANE, Calif., July 14, 2026 Annexon announced that new analyses from its Phase 2 ARCHER trial evaluating vonaprument in...
i-Lumen Advances AMD Trial With FDA IDE Approval
BLOOMINGTON, Minn., USA, March 31, 2026 i-Lumen Scientific has received FDA Investigational Device Exemption (IDE) approval to initiate U.S....
Advertisement
